Detalles de la búsqueda
1.
A hybrid automated event adjudication system for clinical trials.
Clin Trials
; 20(2): 166-175, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36734212
2.
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
Lancet
; 398(10306): 1133-1146, 2021 09 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34469765
3.
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes.
Cardiovasc Diabetol
; 21(1): 158, 2022 08 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35996147
4.
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.
Eur Heart J
; 42(26): 2565-2573, 2021 07 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33197271
5.
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial.
Stroke
; 52(8): 2494-2501, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33985364
6.
Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study.
Lancet
; 395(10226): 785-794, 2020 03 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31492501
7.
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Stroke
; 51(10): 2901-2909, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32951537
8.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet
; 394(10193): 121-130, 2019 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31189511
9.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Lancet
; 394(10193): 131-138, 2019 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31189509
10.
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
N Engl J Med
; 377(14): 1319-1330, 2017 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28844192
11.
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
Gastroenterology
; 157(2): 403-412.e5, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31054846
12.
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Gastroenterology
; 157(3): 682-691.e2, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31152740
13.
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Cardiovasc Diabetol
; 19(1): 199, 2020 11 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33239067
14.
Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial.
Diabetes Obes Metab
; 21(6): 1502-1505, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30785660
15.
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
Diabetes Obes Metab
; 20(1): 42-49, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28573765
16.
Use of Repeated Blood Pressure and Cholesterol Measurements to Improve Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis.
Am J Epidemiol
; 186(8): 899-907, 2017 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28549073
17.
Wealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries.
Int J Equity Health
; 15(1): 199, 2016 12 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27931255
18.
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
N Engl J Med
; 367(4): 309-18, 2012 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-22686415
19.
Basal insulin and cardiovascular and other outcomes in dysglycemia.
N Engl J Med
; 367(4): 319-28, 2012 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-22686416
20.
C-reactive protein, fibrinogen, and cardiovascular disease prediction.
N Engl J Med
; 367(14): 1310-20, 2012 Oct 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-23034020